New antibody plus gentle radiation for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new antibody drug (QL-1706) combined with a special low-dose radiation technique for people with advanced esophageal, lung, or cervical cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow disease growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer, non-small cell lung cancer, or cervical cancer that has been confirmed by a biopsy.
- Your cancer has grown or come back after your first round of standard treatment.
- You have at least one tumor outside your brain that can be measured on scans.
- You are between 18 and 75 years old and in generally good health (able to be up and about).
- Your blood counts, liver and kidney function meet certain minimum levels (doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether adding a new drug called QL1706 to standard chemotherapy (two common cancer drugs) works better for advanced esophageal cancer that can't be surgically removed. The goal is to see if this combination helps patients live longer and controls the cancer better than chemotherapy alone.
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.